colchicine + dexamethasone + pentoxifylline

This is a combination therapy consisting of three small molecule drugs—colchicine, dexamethasone, and pentoxifylline—each with distinct anti-inflammatory mechanisms. Colchicine disrupts microtubule polymerization, inhibiting neutrophil activity and multiple inflammatory pathways. Dexamethasone is a synthetic glucocorticoid that suppresses inflammation by modulating gene expression and cytokine production via the glucocorticoid receptor. Pentoxifylline is a methylxanthine derivative that acts as a non-specific phosphodiesterase inhibitor, increasing cAMP levels and reducing proinflammatory cytokines such as TNF-α; it also improves blood flow by decreasing blood viscosity. This combination has been explored in clinical settings for conditions characterized by severe or refractory inflammation (such as aphthous ulcers or COVID-19), leveraging potential synergistic effects on immune modulation and cytokine inhibition[1][4][8].

Other names

colchicine + dexamethasone + pentoxifylline